GE HealthCare is set to launch its latest computed tomography (CT) system, Revolution Vibe, featuring Unlimited One-Beat Cardiac imaging.
The Revolution Vibe system is designed to deliver consistent, high-quality images for patients, even in challenging cases such as atrial fibrillation and heavily calcified coronaries.
It integrates GE HealthCare’s advanced solutions, including ECG-less Cardiac, TrueFidelity DL, SnapShot Freeze 2, and Effortless Workflow’s AI-powered features.
The enhancements facilitate fast and accurate diagnoses, improve patient comfort, and streamline workflows.
They also address the growing global need for advanced diagnostic technologies amid rising cardiovascular disease (CVD) rates, said GE HealthCare.
Revolution Vibe is designed to enhance access to Cardiac CT angiography (CCTA), a non-invasive, cost-effective, and sensitive method for diagnosing coronary artery disease (CAD).
Its Unlimited One-Beat Cardiac imaging offers clear, full-heart images at low doses, to benefit patients with complex conditions, such as atrial fibrillation, breath-holding difficulties, heavily calcified coronaries, in-stent restenosis, and cases without an ECG trace.
GE HealthCare’s TrueFidelity DL and SnapShot Freeze 2 technologies deliver motion-free images, while ECG-less Cardiac simplifies exam preparation.
GE HealthCare molecular imaging and computed tomography president and CEO Jean-Luc Procaccini said: “Expanding access to CCTA is crucial for managing the rising prevalence of CVD, ensuring timely and accurate diagnoses for a larger patient population.
“Our introduction of Revolution Vibe underscores our commitment to this mission.
“The system is designed to encourage the broader adoption of and access to cardiac imaging, combining advanced technology with AI-powered solutions to deliver fast, accurate diagnoses and a more comfortable patient experience.”
In a separate development, GE HealthCare has completed the acquisition of the remaining 50% stake in Nihon Medi-Physics (NMP) from Sumitomo Chemical, securing full ownership.
Formed in 1973 in Tokyo, Japan, NMP specialises in developing and manufacturing radiopharmaceuticals for single photon emission computed tomography (SPECT) and positron emission tomography (PET) molecular imaging procedures.
NMP’s product portfolio includes radiopharmaceuticals used in molecular imaging for neurology, cardiology, and oncology.
As part of the acquisition, GE HealthCare Pharmaceutical Diagnostics (PDx) segment president and CEO Kevin O’Neill has been appointed as NMP president.
Kevin O’Neill said: “We are delighted to welcome Nihon Medi-Physics to GE HealthCare, increasing our existing footprint and offering in Japan, where our contrast media and medical devices are used every day to enable imaging procedures across the country.
Japan is on a path to becoming a leader in the $7bn molecular imaging global marketand a centre of excellence for Asian markets.
“As part of GE HealthCare, NMP will play a key role in that journey, including bringing its deep expertise and scale to global innovators looking to bring next-generation radiopharmaceuticals to the Japan market and beyond.”
